Abstract
Phenotyping is an effective way to identify cohorts of patients with particular characteristics within a population. In order to enhance the portability of a phenotype definition across institutions, it is often defined abstractly, with implementers expected to realise the phenotype computationally before executing it against a dataset. However, unclear definitions, with little information about how best to implement the definition in practice, hinder this process. To address this issue, we propose a new multi-layer, workflow-based model for defining phenotypes, and a novel authoring architecture, Phenoflow, that supports the development of these structured definitions and their realisation as computable phenotypes. To evaluate our model, we determine its impact on the portability of both code-based (COVID-19) and logic-based (diabetes) definitions, in the context of key datasets, including 26,406 patients at North-western University. Our approach is shown to ensure the portability of phenotype definitions and thus contributes to the transparency of resulting studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by HDRUK, NIHR BRC, NIGMS (R01GM105688) and NHGRI (U01HG8673).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used by King's College London researchers were approved for access by the GSTT BRC Covid Data Analytics Research Data Warehouse governance board under 20/HRA/1871. The data used by Northwestern University researchers were approved for access by the Northwestern University Institutional Review Board under protocol STU00027497.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Various points of clarification throughout the text, as well as cosmetic updates and additional literature coverage.
Data Availability
This manuscript references, and is supported by, both private data from the Northwestern Medicine Enterprise Data Warehouse (NMEDW), data availabe on request from Guy's and St Thomas' Hospitals NHS Trust, and public data from PheKB.
